首页 | 本学科首页   官方微博 | 高级检索  
     


The RSV fusion receptor: not what everyone expected it to be
Authors:Peter Mastrangelo  Richard G. Hegele
Affiliation:1. Laboratory of Virology, Department of Microbiology and Parasitology, Facultad de Medicina, Universidad Nacional Autónoma de México, Avenida Universidad 3000, Ciudad Universitaria, México, D.F. 04360, Mexico;2. Department of Molecular Biomedicine, Centro de Investigación y Estudios Avanzados del Instituto Politécnico Nacional, Av. Instituto Politécnico Nacional 2508, México, D.F. 07360, Mexico;1. Department of Pediatrics, Emory University, Atlanta, GA, USA;2. Children’s Healthcare of Atlanta, Atlanta, GA, USA;3. Department of Medical Zoology, Kyung Hee University School of Medicine, Seoul, Republic of Korea;4. Department of Microbiology and Immunology, Emory University, Atlanta, GA, USA;5. Center for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA;6. Department of Pathology, University of Georgia College of Veterinary Medicine, Athens, GA, USA;1. Division of Pediatric Infectious Diseases, Emory University School of Medicine, 2015 Uppergate Dr, Atlanta, GA 30322, USA;2. Novartis Vaccines and Diagnostics, 350 Massachusetts Ave., Cambridge, MA 02139, USA;3. KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Research – Coast, PO Box 230, Kilifi 80108, Kenya;4. School of Life Sciences, University of Warwick, Coventry CV4 7AL, United Kingdom;5. Novartis Vaccines and Diagnostics Srl, Via Fiorentina 1, 53100 Siena, Italy;6. MRC Unit, The Gambia, PO Box 273, Banjul, Gambia;7. NIAID, NIH Vaccine Research Center Bldg. 40, Rm. 2502 40 Convent Drive MSC 3017, Bethesda, MD 20892, USA;1. Department of Microbiology and Parasitology, Faculty of Medicine, National Autonomous University of Mexico, Ciudad Universitaria, Delegación Coyoacán, Mexico City, C.P. 04510, Mexico;2. Oncogenomics Laboratory, National Institute of Genomic Medicine, Periférico Sur No. 4809, Colonia Arenal Tepepan, Delegación Tlalpan, Mexico City, C.P. 14610, Mexico;1. Interdisciplinary Graduate Program in Immunology, University of Iowa, Iowa City, IA, USA;2. Department of Microbiology and Immunology, University of Iowa, Iowa City, IA, USA;3. Department of Pathology, University of Iowa, Iowa City, IA, USA
Abstract:This article reviews current knowledge about respiratory syncytial virus (RSV) binding and entry into cells. The recent discovery of Nucleolin as a fusion receptor for RSV opens new avenues for developing interventions, while raising questions concerning RSV pathobiology and tropism. We also discuss characteristics of a good RSV drug target.
Keywords:
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号